课题基金 / 基金详情

Hyperphosphorylated tau and the molecular mechanisms of tauopathy

Hyperphosphorylated tau and the molecular mechanisms of tauopathy
过度磷酸化的 tau 蛋白和 tau 蛋白病的分子机制
批准号:
10447253
负责人:
Min-Hao Kuo
金额:
$133.79万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-06-01 至 2025-05-31

项目摘要

项目成果

Min-Hao Kuo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Hyperphosphorylated tau and the molecular mechanisms of tauopathy Tauopathies are neurodegenerative disorders sharing the common pathology of the tau protein in the central nervous system. The most prominent tauopathy is Alzheimer’s disease (AD) that affects nearly 6 million Americans and more than 30 million people worldwide. Animal and cell studies demonstrated that soluble, oligomeric hyperphosphorylated tau is toxic to cells, and can transmit in a prion-like fashion in the brain. However, how hyperphosphorylation converts tau into a cytotoxic species, and how hyperphosphorylated tau exerts its cytotoxicity are unclear. As such, development of efficacious tauopathy therapeutics remains a formidable challenge. This R01 project aims to use a recombinant hyperphosphorylated tau (p-tau) as the model to examine the molecular mechanisms underlying tauopathies. Specifically, we wish to answer two major questions: how does hyperphosphorylated tau damage or kill cells? And what makes tau a cytotoxic species? We will perform proteomics studies to identify targets of p-tau that may lead to the realization of novel druggable targets for future therapeutics design. We will also pinpoint the phosphorylatable residues of the tau protein that, upon modification, drive the genesis and transmission of a pathogenic species. Finally, we have found that the formation of cytotoxic p-tau fibrils is subjected to the regulation of the ApoE lipoprotein and of selective metabolites of cholesterol. Biochemical and cell studies are to be performed to unravel the molecular details, which will facilitate our understanding of how different ApoE alleles contribute to the development of Alzheimer’s disease, as well as how cholesterol metabolism is mechanistically linked to this devastating disease.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
A novel non-transgenic fly model for tauopathies
  • 批准号:
    10662019
  • 项目类别:
  • 资助金额:
    $23.48万
  • 财政年份:
    2023
  • 负责人:
    Min-Hao Kuo
  • 依托单位:
ePIMAX-RCR: Controlled expression of post-translationally modified proteins in eukaryotes
  • 批准号:
    10095625
  • 项目类别:
  • 资助金额:
    $23.48万
  • 财政年份:
    2020
  • 负责人:
    Min-Hao Kuo
  • 依托单位:
ePIMAX-RCR: Controlled expression of post-translationally modified proteins in eukaryotes
  • 批准号:
    10263311
  • 项目类别:
  • 资助金额:
    $19.56万
  • 财政年份:
    2020
  • 负责人:
    Min-Hao Kuo
  • 依托单位:
Hyperphosphorylated tau aggregation-based Alzheimer’s disease early drug discovery
  • 批准号:
    9904313
  • 项目类别:
  • 资助金额:
    $43.67万
  • 财政年份:
    2019
  • 负责人:
    Min-Hao Kuo
  • 依托单位:
海外基金